CJC-1295 + Ipamorelin: Is There Human Evidence for the Combination?

Short answer

In the sources reviewed as of September 1, 2026, we did not identify a human interventional trial that administered CJC-1295 and Ipamorelin together. We also did not identify a ClinicalTrials.gov trial of the exact pair.^1,7,4,9

The human evidence that does exist belongs to each component separately, or to other molecules in the GHRH and GHS or ghrelin classes. That evidence is not added together. The cluster hub is CJC-1295 + Ipamorelin: component evidence versus blend evidence.

This page is an inventory, not a product sheet. It does not recommend a use, does not describe an administration scheme, and does not turn an evidence gap into a promise.

Evidence-audit matrix

The table below classifies sources that are often invoked as if they spoke about the blend. The last column is the editorial question: did the study administer the exact CJC-1295 + Ipamorelin pair?

Bowers 1990 studied a growth hormone-releasing peptide other than Ipamorelin together with GHRH other than CJC-1295, in healthy men. Arvat 2001 studied ghrelin, hexarelin, and GHRH. Neither paper is the commercial pair.^10,11

Teichman 2006 administered long-acting CJC-1295, the DAC form, to healthy adults. Gobburu 1999 modeled ipamorelin in volunteers. Beck 2014 randomized ipamorelin in postoperative ileus. Three papers, two molecules, zero blend.^1,6,7

Mayfield 2026 is a narrative sports-medicine review. Its results text attributes a murine maximum-tetanic-tension finding to CJC-1295 combined with ipamorelin. The primary citations for that passage do not administer that pair. Detail is below.^13,14

Both components can increase GH — separately

Teichman and colleagues, in two randomized, placebo-controlled, ascending-dose studies, measured sustained increases in growth hormone and IGF-I after long-acting CJC-1295 in healthy adults aged 21 to 61 years. The endpoints were hormonal and pharmacokinetic. They were not body composition, performance, or combination endpoints.¹

Ionescu and Frohman showed that growth-hormone pulsatility persisted during that continuous stimulation. Sackmann-Sala analyzed serum protein profiles from an existing cohort. Those papers extend the physiology of the DAC component. They do not create an Ipamorelin arm.^2,3

NCT00267527 registered a Phase 2 trial of CJC-1295 in patients with HIV and visceral obesity. The record is Terminated. As of the 1 September 2026 review it posts no results, and registry status alone does not establish why the study stopped. It is also not a blend study.⁴

Gobburu and colleagues modeled ipamorelin pharmacokinetics and growth-hormone response in forty healthy male volunteers at five infusion-rate levels. That is human pharmacology of the component. It is not a fat, muscle, sleep, or blend trial.⁶

Raun and colleagues characterized ipamorelin as a selective secretagogue in rat pituitary cells, rats, and swine. That paper is preclinical. Laboratory selectivity is not unconditional human safety language and is not combination evidence.⁵

Beck and colleagues published a prospective, randomized, controlled Phase 2 trial of ipamorelin for postoperative ileus after bowel resection. Enrollment was 117; the safety and modified intention-to-treat set was 114. The key endpoint — time to tolerate a standardized solid meal — did not reach a statistically significant difference.^7,8

NCT01280344 registered another Phase 2 trial of ipamorelin versus placebo for recovery of gastrointestinal function, with 320 participants. The record is Completed, with study completion in May 2014. As of the 1 September 2026 review it posts no numerical results. A completed registry is not an efficacy paper, and it is not a trial of the exact pair.⁹

That both components, in different designs, can move growth hormone does not authorize addition. CJC-1295-alone evidence plus Ipamorelin-alone evidence is not combination evidence. A reader who treats the two axes as one program is reading a catalog, not the sources.^1,6

The synergy claim

The synergy sentence that circulates around the blend usually starts with Bowers 1990. That paper, in healthy men, describes a GHRP acting synergistically with GHRH on growth-hormone release. The molecules are not Ipamorelin or CJC-1295.¹⁰

Arvat 2001 adds interactions of ghrelin and hexarelin with GHRH. Again: class analogy, not the commercial pair. One may formulate, as a mechanistic hypothesis extrapolated from that other literature, that two distinct pathways could interact on growth-hormone secretion. That hypothesis is not a human result for the blend, and it does not authorize saying that “CJC-1295 and Ipamorelin work synergistically” or that “the blend produces synergistic GH release” as if those sentences had been measured.^11,10

Receptor detail is in GHRH, ghrelin, and two signaling pathways. Mechanism explains the interest. It does not fill the empty cell in the matrix.

Animal claims and the Mayfield 2026 error

Mayfield and colleagues, 2026, published a narrative review for orthopaedic and sports-medicine physicians. In the results text, the review states that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss.¹³

That sentence describes a pair. The primary citations supporting the passage do not administer that pair. Andersen and colleagues, 2001, studied ipamorelin alone in adult rats under glucocorticoid exposure, with bone-formation outcomes. Johansen and colleagues, 1999, studied ipamorelin alone and longitudinal bone growth in rats.^14,15

Later, Mayfield’s own body text describes Andersen as subcutaneous ipamorelin reducing muscle atrophy or osteopenia in that model. That later description names one molecule. The results text, by contrast, names the combination. The review claim does not match the molecules the primary experiments actually administered.^13,14

Even if Andersen were read only as an ipamorelin paper, it would remain a rat study under glucocorticoids, with bone and tissue outcomes in that model. It is not a human trial of the blend, not a sports-performance result, and it is not translated here into an indication.¹⁴

Human outcomes not established for the blend

In the sources reviewed as of September 1, 2026, we did not identify human evidence for the exact pair that established body composition, recovery, performance, sleep, or long-term safety. The list names gaps. It is not a menu of benefits waiting to be confirmed.^1,7,13

Growth-hormone or IGF-I increases measured with each component separately do not fill those gaps. An endocrine signal is not a composition, sleep, or performance outcome, and it is not inherited from a single-peptide paper onto a two-peptide vial.^1,2,6

Beck 2014 also does not fill a “recovery” gap in a sports or repair sense. Its question was postoperative ileus, and the key endpoint was not significant. NCT01280344, completed with no results posted in this review, is not read as a hidden number in favor of the blend.^7,9

• In the sources reviewed as of September 1, 2026, we did not identify a human trial of the exact pair for body composition.^1,13
• We did not identify that trial for recovery, performance, or sleep.^7,9
• We did not identify a long-term safety program for the blend.¹²

The components have their own pages: CJC-1295 in humans and Ipamorelin in humans. Those pages are not combined here into a third clinical program.

A certificate of analysis is not clinical biology

A blend certificate of analysis can establish analytical properties of a lot: identity, reported purity, and the methods the laboratory declares. That matters for knowing what is in the vial. It does not validate a clinical interaction between the two molecules, does not measure joint growth hormone, and does not demonstrate pharmacodynamic synergy.

Analytical identity and interaction evidence are different questions. A lot can be well characterized and still have no human trial of the pair behind it. The COA does not fill the last row of the matrix.

A commercial “blend” name also does not turn Teichman or Gobburu into combination studies. The vial label does not change what was administered in 1999, 2006, or 2014.^1,6,7

If the question is how two pathways are read on the somatotroph, go back to GHRH and ghrelin mechanism. If the question is what has been measured in people with each peptide, those component pages remain the right place. This page stops where invention of the pair begins.